GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (OTCPK:HBMHF) » Definitions » Net Margin %

HBM Holdings (HBM Holdings) Net Margin % : 40.97% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. HBM Holdings's Net Income for the six months ended in Dec. 2023 was $19.88 Mil. HBM Holdings's Revenue for the six months ended in Dec. 2023 was $48.51 Mil. Therefore, HBM Holdings's net margin for the quarter that ended in Dec. 2023 was 40.97%.

The historical rank and industry rank for HBM Holdings's Net Margin % or its related term are showing as below:

HBMHF' s Net Margin % Range Over the Past 10 Years
Min: -3198.18   Med: -1672.97   Max: 25.47
Current: 25.45


HBMHF's Net Margin % is ranked better than
92.05% of 1032 companies
in the Biotechnology industry
Industry Median: -156.25 vs HBMHF: 25.45

HBM Holdings Net Margin % Historical Data

The historical data trend for HBM Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Net Margin % Chart

HBM Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial -1,244.88 -2,101.06 -3,198.17 -337.49 25.47

HBM Holdings Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -3,636.31 -264.39 -492.52 7.13 40.97

Competitive Comparison of HBM Holdings's Net Margin %

For the Biotechnology subindustry, HBM Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HBM Holdings's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where HBM Holdings's Net Margin % falls into.



HBM Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

HBM Holdings's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=22.797/89.502
=25.47 %

HBM Holdings's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=19.875/48.506
=40.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HBM Holdings  (OTCPK:HBMHF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


HBM Holdings Net Margin % Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


HBM Holdings (HBM Holdings) Business Description

Traded in Other Exchanges
Address
420 Fenglin Road, 12th Floor, Tower A, Fenglin International Plaza Phase II, Xuhui District, Shanghai, CHN, 200032
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. Majority of revenue is generated from Europe.

HBM Holdings (HBM Holdings) Headlines

From GuruFocus

Harbour BioMed Announces Positive Profit Alert

By PRNewswire 01-19-2024